VANCOUVER, BC and MESA, AZ, Oct. 28,
2013 /CNW/ - Avidus Management Group Inc. ("Avidus" or the
"Company") (TSX-V: AVD, OTC: ASNHF) is pleased to announce that,
further to its news release dated October
11, 2013, the Company has completed a non-brokered private
placement of 5,333,290 units (the "Units") at a price of
$0.15 per Unit for gross proceeds of
approximately $800,000 (the
"Offering").
Insiders, namely the Honorable John Reynolds, Chairman,
Daniel Lundell, CEO and Douglas Ridley, President, led the Offering,
cumulatively investing $430,039 of
the $800,000.
Each Unit consists of one common share of the Company (a
"Share") and one common share purchase warrant (a "Warrant").
Each whole Warrant entitles the holder to purchase an additional
common share of the Company at an exercise price of $0.20 per common share for a period of five years
from the date of issue; provided, however, that the Company will be
entitled to accelerate the expiry date of the Warrants to the date
that is 10 days following the date that the Company provides notice
to holders that the closing price of the common shares on the
Exchange has been equal to or greater than $0. 45 for 10 consecutive trading days prior
thereto. All securities issued under the private placement
are subject to a four-month statutory hold period.
In connection with the Offering, the Company issued a total of
86,800 non-transferrable broker warrants (the "Broker Warrants")
and paid cash finder's fees equal to $13,020. Each Broker Warrant entitles the
holder thereof to purchase one common share of the Company at a
price of $0.20 per share for a period
of 18 months.
The net proceeds from the Offering will be used for general
corporate and working capital purposes.
About Avidus
Avidus Management Group Inc. (TSX-V: AVD, OTC:
ASNHF) through its wholly owned subsidiary, Asantae
(www.asantae.com) develops, produces and markets innovative
nutritional products through direct and network marketing channels.
The ingredients in Asantae's products have been shown to reduce
chronic low-grade inflammation and oxidative stress, and support a
healthy immune system that, according to scientific and medical
research, are the underlying conditions for most modern epidemic
diseases (diabetes, heart disease, obesity, stroke,
etc.).
This news release may contain forward-looking statements
relating to the Company's operations or to the environment in which
it operates. Such statements are based on operations, estimates,
forecasts and projections. They are not guarantees of future
performance and involve risks and uncertainties that are difficult
to predict and may be beyond the Company's control. A number of
important factors could cause actual outcomes and results to differ
materially from those expressed in forward-looking statements,
including those set forth in the Company's regulatory filings. In
addition, such statements relate to the date on which they are made
and the Company disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, save and except as may be
required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Avidus Management Group Inc.